In conclusion, our present results suggest that amarogentin affects liver cancer angiogenesis via the p53-dependent VEGFA/Dll4/Notch1 pathway in CD133-positive cells after iRFA treatment, implying a novel supplementary strategy for the treatment of residual liver cancer after iRFA treatment. The gene discussed is TP53; the disease is liver cancer.